OrthoPediatrics Reports $70.5M Revenue in Q2 2026, Net Loss of $7.2M

OrthoPediatrics Corp. reported a net revenue of $70.5 million for the second quarter of 2026, marking a 15% increase from $61.1 million in the same period of 2025. For the first half of 2026, the company achieved revenues of $129.9 million, up 14% from $113.5 million year-over-year. The growth was primarily driven by strong sales in the Trauma and Deformity segment, which saw a 26% increase in the second quarter, totaling $52.6 million. Despite the revenue growth, the company reported a net loss of $7.2 million for the quarter, slightly higher than the $7.1 million loss in the prior year.

In terms of operational metrics, OrthoPediatrics experienced a rise in accounts receivable, which increased to $61.0 million from $53.8 million, reflecting improved sales performance. The company also reported a gross profit margin of 74% for both the second quarter and the first half of 2026, consistent with the previous year. However, total operating expenses rose to $56.4 million for the quarter, up from $54.7 million, driven by increased sales and marketing expenses as well as general and administrative costs associated with clinic expansions and acquisitions.

Strategically, OrthoPediatrics has been active in expanding its market presence through acquisitions. The company completed the purchase of Medtech Concepts, LLC in May 2023, which has contributed to its product offerings. Additionally, the company has made several acquisitions in the orthotic and prosthetic space, including clinics in the U.S. and Europe, which are expected to enhance its operational capabilities and market reach. As of June 30, 2026, the company reported goodwill of $118.5 million, up from $109.3 million at the end of 2025, reflecting these acquisitions.

Looking ahead, OrthoPediatrics anticipates continued investment in its product portfolio and expansion into new markets, which may lead to ongoing operating losses in the near term. The company had cash and cash equivalents of $19.1 million as of June 30, 2026, down from $21.6 million at the beginning of the year, but remains in compliance with its debt covenants. The management believes that its current cash position, along with expected cash flows from operations, will be sufficient to support its operations for the next twelve months. The company is focused on enhancing its sales infrastructure and expanding its product offerings to capture a larger share of the pediatric orthopedic market, which it estimates to be a $6.2 billion opportunity globally.